Other Routine +

Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:30 SEGN · 0.32 Seegnal Inc.

Executive Summary

Seegnal Inc. signed a five-year agreement to deploy its clinical decision support SaaS platform at Nazareth Hospital EMMS, a major regional trauma and teaching center in northern Israel.
The deployment will support approximately 424 medical staff members (188 physicians and 236 nurses) integrated into routine prescribing workflows.
The deal features recurring subscription fees over the initial term with an extension option.
The platform is now utilized by approximately 15,000 clinicians across Israeli healthcare settings.
The release highlights peer-reviewed clinical performance metrics, including 94% fewer inpatient alerts with 99% specificity and reductions in hospitalizations and medication dispensing.

Material Impact

The Nazareth Hospital agreement represents a standard, incremental commercial expansion within Seegnal's established Israeli market. It adds predictable recurring revenue but is immaterial to the company's overall financial profile given its micro-cap status and current cash burn.
The deal does not alter the company's fundamental risk profile. It does not address the material going-concern uncertainty, negative working capital, or the need for larger-scale capital raises to fund U.S. expansion and R&D.
The clinical metrics cited are consistent with prior management commentary and do not represent new, unexpected data that would re-rate the business model.

SEGN · Price

Company Overview

Seegnal Inc. is an Israeli-based med-tech SaaS company developing a clinical decision support system focused on medication safety and prescription intelligence.
The platform integrates patient-specific data (medications, lab results, renal function, allergies, age) to deliver context-aware alerts, aiming to reduce alert fatigue, adverse drug events, and hospitalizations.
The technology is currently deployed across Israeli healthcare settings, utilized by over 15,000 clinicians, and processes more than 400,000 prescriptions daily.
Management is actively pursuing commercial expansion into the United States, targeting long-term care and nursing facilities, while maintaining its core Israeli operations.

More from Seegnal Inc.